Boehringer Ingelheim refocuses Gly-T1 inhibition brain research on schizophrenia
Boehringer Ingelheim refocuses Gly-T1 inhibition brain research on schizophrenia
Search
Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes
Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
The Research Process
The Research Process
New consortium EUbOPEN will provide tools to unlock disease biolog
New consortium EUbOPEN will provide tools to unlock disease biolog
Results announced from EMPACT-MI phase III trial
Results announced from EMPACT-MI phase III trial in adults following a heart attack.
Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis
Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis
IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function
IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function
Biosimilars
: A biosimilar is a version of a biologic medication that is made by a different company than the one that invented it, with no clinically meaningful differences in terms of safety, potency and purity.
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
New analysis supports long-term treatment with Ofev® in SSc-ILD patients
New analysis supports long-term treatment with Ofev® in SSc-ILD patients
Technologies
We are expanding our global network of technology partners. Learn more about partnering with us.
Jardiance® (empagliflozin) Granted Designation for Heart Failure | Boehringer Ingelheim US
The FDA granted Breakthrough Therapy designation for JARDIANCE® (empagliflozin) as treatment for HFpEF. View ISI, PI and Med Guide.
Our forward-looking approach drives breakthroughs
Our purpose is the patient—so our actions are those of a partner, our vision is always long-term, and our results are measured in lives changed and lives saved.
US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fractio
US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fraction
Biosimilars
Biosimilars
Novel antibody shows potential to transform treatment of rare form of psoriasis
Novel antibody shows potential to transform treatment of rare form of psoriasis
Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
A Moment To Reflect on the Evolving Approach for Diabetes Management | Boehringer Ingelheim US
A Moment To Reflect on the Evolving Approach for Diabetes Management
FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
Baseball Legend Bernie Williams Calls on the Public to Join Queen Latifah, The Bacon Brothers, Paul Shaffer, as Judges of the Breathless® Ballad Challenge
Baseball Legend Bernie Williams Calls on the Public to Join Queen Latifah, The Bacon Brothers, Paul Shaffer, as Judges of the Breathless® Ballad Challenge
BI & Lilly Announce Outcome of FDA Advisory Meeting | Boehringer Ingelheim US
The EASE phase III program includes two Phase III clinical trials to investigate the efficacy, safety and tolerability of once-daily Empagliflozin.
US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes
US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes
Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control
Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control
Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis
Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis